

THE NEW NORMAL IN EXPLORATORY CLINICAL TRIALS: CHALLENGES AND FUTURE TRENDS

In today's fast-changing world, staying competitive requires innovative thinking and adaptability. With the rise of novel technologies, keeping the pulse on developments has become more critical than ever before. The Clinical Development industry is facing competition with unprecedented challenges caused by disruptive events. Application of innovative strategies has proven that early phase clinical trials can maintain necessary flexibility and can be executed on time and within budget.

After 3 years of virtual meetings, we are excited to meet face-to-face for an interactive roundtable discussion. In an informal setting, industry thought leaders will have an opportunity to exchange their vision of paradigm shifts in early clinical development. The focus will be on practical aspects of the new normal in planning and execution of early phase clinical trials.

Among other exciting topics, we will discuss:

- ✓ Understanding that Early Phase Trials are not small-scale Phase III trials
- ✓ Enhancing Cohort Management through reducing the number of sites
- ✓ Strategies for flexibility and resilience embedded into study designs
- ✓ Future Concepts for Early Phase Clinical Trials

AGENDA:

18:00–18:30	Registration, Networking & Cocktails
18:30–19:00	Welcome and Introduction New normal in exploratory clinical trials. Challenges and Future Trends. Dr. Claudia Hesselmann, PhD, Co-founder & CEO, ARENSIA
19:00–20:00	Roundtable Discussion Accelerated performance of complex exploratory patient studies: Practical insights from investigational site Dr. Natalia Pirtac, Manager Trial Optimization, Germany, ARENSIA
20:00–20:30	Dinner
20:30–21:30	Roundtable Discussion (Continued)
21:30–22:30	Closing Remarks Coffee etc

KEY OPINION LEADERS:



Dr. Claudia Hesselmann, PhD, Co-founder & CEO, ARENSIA

Claudia Hesselmann, a chemist by training with PhD in molecular biology, has 20 years expertise in the early phases of drug development. This includes co-founding and holding management positions in various CROs. With extensive experience and based on long-time networking in the pharmaceutical industry, Claudia has co-founded ARENSIA Exploratory Medicine in Düsseldorf, Germany with the aim to contribute with innovative approaches to substantial acceleration of the drug development process, thus enabling patients' access to novel medicines faster.



Dr. Natalia Pirtac, Manager Trial Optimization, Germany, ARENSIA

Natalia Pirtac, a medical doctor by education, has 10+ years of experience in early-phase clinical trials covering oncology and multi-therapeutic areas. Natalia has held several positions within ARENSIA, including study coordinator and sub-investigator. Along with her operational responsibilities, Natalia is developing and maintaining relationships with ARENSIA's partners to facilitate thorough feasibility inquiries and efficient study planning.

WWW.ARENSIA-EM.COM

ARENSIA EXPLORATORY MEDICINE is a German operator of proprietary research clinics, dedicated to performing complex Phase Ib, IIa and PROOF-OF-CONCEPT clinical trials with novel molecules, involving patients across numerous disease areas. Given the outstanding patient recruitment rates achieved by ARENSIA clinics, we are able to substantially reduce the overall number of sites, countries and recruitment periods for any early phase patient trial.